Hyperimmunoglobulin D syndrome in childhood

Current Rheumatology Reports

Volumn 12, Issue 2, 2010, Pages 101-107

  Van Der Hilst, Jeroen C H ^a   Frenkel, Joost ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anakinra; HIDS; Immunoglobulin D; Mevalonate kinase deficiency

Indexed keywords

ATORVASTATIN; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; INFLIXIMAB; MEVALONATE KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; THALIDOMIDE;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; LABORATORY TEST; MEVALONIC ACIDURIA; PATHOGENESIS; QUALITY OF LIFE; REVIEW;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEVER; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MEVALONATE KINASE DEFICIENCY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SYNDROME;

EID: 77953478561     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0086-1     Document Type: Review

References (39)

1. Drenth JPH, van der Meer JWM: Hereditary periodic fever. N Engl J Med 2001, 345:1748-1757.
2. van der Hilst JC, van der Meer JW, Drenth JP: Autoinflammatory fever syndromes. In Clinical Immunology: Principles and Practice, edn 3. Edited by Rich RR. St Louis, MO: Mosby; 2008.
3. Aksentijevich I, Masters SL, Ferguson PJ, et al.: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
4. Masters SL, Simon A, Aksentijevich I, Kastner DL: Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668. This excellent review on the pathogenesis of the autoinflammatory diseases focuses on the molecular pathways that lead to inflammation.
5. Drenth JP, Cuisset L, Grateau G, et al.: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178-181.
6. Houten SM, Kuis W, Duran M, et al.: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
7. Simon A, Drewe E, van der Meer JW, et al.: Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004, 75:476-478.
8. Mandey SH, Kuijk LM, Frenkel J, Waterham HR: A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006, 54:3690-3695.
9. Kuijk LM, Mandey SH, Schellens I, et al.: Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol 2008, 45:2158-2165. This elegant in vitro study further elucidated the importance of isoprenoids in the activation of caspase-1 and interleukin-1β secretion.
10. Kuijk LM, Beekman JM, Koster J, et al.: HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008, 112:3563-3573.
11. Normand S, Massonnet B, Delwail A, et al.: Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 2009, 20:101-107.
12. Bodar EJ, van der Hilst JC, van Heerde W, et al.: Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 2007, 109:2416-2418.
13. van der Meer JWM, Vossen JM, Radl J, et al.: Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984, 1:1087-1090.
14. van der Hilst JC, Bodar EJ, Barron KS, et al.: Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008, 87:301-310. The largest study of HIDS patients so far described the clinical characteristics and follow-up of 103 patients. It also showed that HIDS significantly impairs the quality of life.
15. Steichen O, van der Hilst J, Simon A, et al.: A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 2009, 36:1677-1681.
16. Drenth JP, Haagsma CJ, van der Meer JW: Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994, 73:133-144.
17. Kone-Paut I, Sanchez E, Le QA, et al.: Autoinflammatory gene mutations in Behcet's disease. Ann Rheum Dis 2007, 66:832-834.
18. Kraus CL, Culican SM: Nummular keratopathy in a patient with Hyper-IgD Syndrome. Pediatr Rheumatol Online J 2009, 7:14.
19. van der Hilst JC, Simon A, Drenth JP: Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005, 5:87-98.
20. van der Hilst JC, Simon A, Drenth JP: Molecular mechanisms of amyloidosis. N Engl J Med 2003, 349:1872-1873.
21. Obici L, Manno C, Muda AO, et al.: First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004, 50:2966-2969.
22. Lachmann HJ, Goodman HJ, Andrews PA, et al.: AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis Rheum 2006, 54:2010-2014.
23. van der Hilst JC, Drenth JP, Bodar EJ, et al.: Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid 2005, 12:115-119.
24. Houten SM, Wanders RJ, Waterham HR: Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochim Biophys Acta 2000, 1529:19-32.
25. Cuisset L, Drenth JP, Simon A, et al.: Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 2001, 9:260-266.
26. Simon A, van der Meer JW, Vesely R, et al.: Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) 2006, 45:269-273.
27. Federici L, Rittore-Domingo C, Kone-Paut I, et al.: A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis 2006, 65:1427-1432.
28. Di Rocco M, Caruso U, Waterham HR, et al.: Mevalonate kinase deficiency in a child with periodic fever and without hyperimmunoglobulinaemia D. J Inherit Metab Dis 2001, 24:411-412.
29. Dode C, Andre M, Bienvenu T, et al.: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002, 46:2181-2188.
30. Medlej-Hashim M, Petit I, Adib S, et al.: Familial Mediterranean Fever: association of elevated IgD plasma levels with specific MEFV mutations. Eur J Hum Genet 2001, 9:849-854.
31. Ammouri W, Cuisset L, Rouaghe S, et al.: Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 2007, 46:1597-600. This study showed that serum IgD values do not predict which patients with a clinical suspicion of HIDS actually have mutations in MVK.
32. Rait DS, Ostroff JS, Smith K, et al.: Lives in a balance: perceived family functioning and the psychosocial adjustment of adolescent cancer survivors. Fam Process 1992, 31:383-397.
33. Stam H, Grootenhuis MA, Last BF: The course of life of survivors of childhood cancer. Psychooncology 2005, 14:227-238.
34. Stam H, Hartman EE, Deurloo JA, et al.: Young adult patients with a history of pediatric disease: impact on course of life and transition into adulthood. J Adolesc Health 2006, 39:4-13.
35. Drenth JP, Vonk AG, Simon A, et al.: Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 2001, 298:1221-1226.
36. Bodar EJ, van der Hilst JC, Drenth JP, et al.: Effect of etanercept and anakinra on inflammatory attacks in the Hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005, 63:24-28.
37. Takada K, Aksentijevich I, Mahadevan V, et al.: Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003, 48:2645-2651.
38. Nevyjel M, Pontillo A, Calligaris L, et al.: Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. Pediatrics 2007, 119:e523-e527.
39. Rigante D, Ansuini V, Bertoni B, et al.: Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006, 27:97-100.